Sodium–glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with …

E Patorno, PT Htoo, RJ Glynn… - Annals of internal …, 2021 - acpjournals.org
Background: Both sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like
peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo …

[HTML][HTML] Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease

VR Varma, RJ Desai, S Navakkode, LW Wong… - Molecular …, 2023 - nature.com
We recently nominated cytokine signaling through the Janus-kinase–signal transducer and
activator of transcription (JAK/STAT) pathway as a potential AD drug target. As …

Association of type of oral anticoagulant dispensed with adverse clinical outcomes in patients extending anticoagulation therapy beyond 90 days after hospitalization …

A Pawar, JJ Gagne, C Gopalakrishnan, G Iyer… - Jama, 2022 - jamanetwork.com
Importance Guidelines for managing venous thromboembolism (VTE) recommend at least
90 days of therapy with oral anticoagulants. Limited evidence exists about the optimal drug …

Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases

MC Schneeweiss, SC Kim, R Wyss, Y Jin… - JAMA …, 2021 - jamanetwork.com
Importance Several studies have linked chronic inflammatory skin diseases (CISDs) with
venous thromboembolism (VTE) in a range of data sources with mixed conclusions …

Epidemiologic characterization of heart failure with reduced or preserved ejection fraction populations identified using Medicare claims

RJ Desai, M Mahesri, K Chin, R Levin, R Lahoz… - The American Journal of …, 2021 - Elsevier
Background Administrative claims do not contain ejection fraction information for heart
failure patients. We recently developed and validated a claims-based model to predict …

Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with rheumatoid arthritis treated with targeted disease-modifying …

RJ Desai, VR Varma, T Gerhard, J Segal… - JAMA network …, 2022 - jamanetwork.com
Importance Cytokine signaling, including tumor necrosis factor (TNF) and interleukin (IL)-6,
through the Janus-kinase (JAK)–signal transducer and activator of transcription pathway …

Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care

RJ Desai, E Patorno, M Vaduganathan, M Mahesri… - Heart, 2021 - heart.bmj.com
Objective To evaluate the effectiveness of angiotensin receptor-neprilysin inhibitor (ARNI)
versus renin-angiotensin system (RAS) blockade alone in older adults with heart failure with …

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study

RJ Desai, VR Varma, T Gerhard, J Segal… - … Research & Clinical …, 2020 - Wiley Online Library
Drug discovery for disease‐modifying therapies for Alzheimer's disease and related
dementias (ADRD) based on the traditional paradigm of experimental animal models has …

[HTML][HTML] External validation of a claims-based model to predict left ventricular ejection fraction class in patients with heart failure

M Mahesri, K Chin, A Kumar, A Barve, R Studer… - PLoS …, 2021 - journals.plos.org
Background Ejection fraction (EF) is an important prognostic factor in heart failure (HF), but
administrative claims databases lack information on EF. We previously developed a model …

A multi-modal approach to evaluate the impact of risk evaluation and mitigation strategy (REMS) programs

A Sarpatwari, M Mitra-Majumdar, K Bykov, J Avorn… - Drug Safety, 2021 - Springer
Abstract Introduction Since 2007, the US Food and Drug Administration has had the
authority to require risk evaluation and mitigation strategy (REMS) programs for certain …